Ocugen (stock symbol: OCGN) Logo in transparent PNG and SVG formats

Ocugen Logo large

Ocugen Logo icon format

Ocugen Logo large for dark backgrounds

Ocugen Logo icon format for dark backgrounds

About Ocugen

Ocugen, Inc., a clinical-stage biopharmaceutical company, focuses on the developing gene therapies to cure blindness diseases. The company's pipeline product includes OCU400, a novel gene therapy product candidate restoring retinal integrity and function across a range of genetically diverse inherited retinal diseases, such as retinitis pigmentosa and leber congenital amaurosis; OCU410, gene therapy candidate for the treatment of dry age-related macular degeneration (AMD); and OCU200, a novel fusion protein that is in preclinical development stage for the treatment of diabetic macular edema, diabetic retinopathy, and wet AMD. Ocugen, Inc. has a strategic partnership with CanSino Biologics Inc. for gene therapy co-development and manufacturing; and Bharat Biotech for the commercialization of COVAXIN in the United States market. The company is headquartered in Malvern, Pennsylvania.

  • Website domain: ocugen.com
  • Employees: 56
  • Marketcap: $0.35 Billion USD

Page last updated on:

August 6th, 2022

Categories: